(Rac)-JBJ-04-125-02

CAS No. 2140807-05-0

(Rac)-JBJ-04-125-02( —— )

Catalog No. M23974 CAS No. 2140807-05-0

JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 262 In Stock
5MG 217 In Stock
10MG 353 In Stock
25MG 598 In Stock
50MG 833 In Stock
100MG 1135 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (Rac)-JBJ-04-125-02
  • Note
    Research use only, not for human use.
  • Brief Description
    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
  • Description
    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR (L858R/T790M )
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2140807-05-0
  • Formula Weight
    543.6
  • Molecular Formula
    C29H26FN5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:240mg/mL (441.5 mM);Water:Insoluble
  • SMILES
    C1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)C(C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
molnova catalog
related products
  • Gefitinib

    A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM; inhibits EGF-stimulated proliferation of KB cells with IC50 of 80 nM.

  • Canertinib dihydroch...

    A potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.

  • Mobocertinib

    Mobocertinib is a potent ?inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent.